However, the 2012 writing group noted that diabetes was not listed as a high-risk feature for which an invasive strategy was specifically preferred, in contrast to the inclusion of chronic kidney disease (CKD) and diabetes mellitus as characteristics favoring an invasive approach in the 2007 European Society of Cardiology guide- lines for management of UA/NSTEMI.160 To revisit this question for diabetes, the writing group reviewed results of the published analysis of patients with diabetes in the FRISC-II (FRagmin and Fast Revascularization during InSta- bility in Coronary artery disease) trial.72 Overall, the FRISC- II trial demonstrated a benefit with invasive management compared with conservative management in patients with UA/NSTEMI. There were similar reductions in the risk of MI/death at 1 year in the diabetic subgroup randomized to an invasive strategy (OR: 0.61; 95% CI: 0.36 to 1.04) compared with patients who did not have diabetes randomized to an invasive strategy (OR: 0.72; 95% CI: 0.54 to 0.95). The risk of death was also reduced by randomization to an invasive strategy among patients with diabetes (OR: 0.59; 95% CI: 0.94). Subgroup analysis of the TACTICS-TIMI-18 (Treat Angina with aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy Thrombolysis In Myocar- dial Infarction 18) study in patients with diabetes, available in abstract form, was consistent with this finding.161 Thus, diabetes, as well as the often concurrent comorbidity of CKD (Section 6.5, Chronic Kidney Disease: Recommendations), is not only a high-risk factor but also benefits from an invasive approach. Accordingly, diabetes has been added to the list of characteristics for which an early invasive strategy is gener- ally preferred (Appendix 6). 6.5. Chronic Kidney Disease: Recommendations (See Table 8, and Online Data Supplement.) 6.5.1. 